H. Lee Moffitt Cancer Center and Research Institute
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
Inclusion Criteria: * Histologically proven diagnosis of Merkel cell carcinoma (MCC). * Clinical stage I-II MCC (AJCC 8th edition) either newly diagnosed or previously diagnosed with recent disease recurrence. This includes patients with a previous diagnosis of clinical Stage I-II who present with local or regional disease recurrence. * Patients must be considered candidates for wide local surgical excision and may be candidates for sentinel lymph node biopsy. If sentinel biopsy is determined to not be clinically indicated then it would not be required to be completed and only the tumor excis…
Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
Arctuva estimate
Verify or correct the compensation shown for this listing.